Financial Performance - Net profit attributable to shareholders was CNY 341,739,218.88, an increase of 37.84% year-on-year[4]. - Operating revenue for the period was CNY 3,338,354,620.60, reflecting a growth of 4.11% compared to the same period last year[4]. - Basic earnings per share rose to CNY 0.11, a 37.50% increase compared to the previous year[4]. - Net profit for the period increased by 36.63% to ¥34,625.95 million from ¥25,342.44 million, supported by high market prices for monosodium glutamate and government subsidies[10]. - Operating profit for Q1 2019 was CNY 413,113,446.80, up from CNY 301,540,282.00 in Q1 2018, reflecting a growth of 37.1%[21]. - Net profit attributable to shareholders for Q1 2019 was CNY 341,739,218.88, compared to CNY 247,924,963.50 in Q1 2018, marking an increase of 37.7%[22]. - Total comprehensive income for Q1 2019 was CNY 52,044,573.76, compared to CNY 14,944,521.34 in Q1 2018, marking a growth of 238.5%[26]. Cash Flow - The net cash flow from operating activities was CNY 289,163,110.76, down 17.54% from the previous year[4]. - Net cash flow from operating activities decreased by 17.54% to ¥28,916.31 million from ¥35,066.37 million, mainly due to increased payments for raw materials and prepayments[11]. - Cash flow from operating activities totaled CNY 3,259,294,494.44 in Q1 2019, compared to CNY 3,188,093,484.98 in Q1 2018, indicating a slight increase of 2.2%[27]. - The net cash flow from operating activities for Q1 2019 was ¥276,378,952.47, a decrease of 46.4% compared to ¥517,870,982.68 in Q1 2018[30]. - Total cash inflow from operating activities was ¥3,570,546,140.53, while cash outflow was ¥3,294,167,188.06, resulting in a net cash flow of ¥276,378,952.47[30]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 18,996,599,635.44, a decrease of 0.36% compared to the end of the previous year[4]. - Total liabilities decreased to CNY 7,702,745,440.17 in Q1 2019 from CNY 7,829,788,499.78 in Q1 2018, a reduction of 1.6%[21]. - Total current assets increased to ¥5,166,505.64 million from ¥5,094,948.39 million, indicating a slight growth in overall asset base[14]. - Non-current assets totaled ¥13,970,080,852.31, with no adjustments reported between the two dates[34]. - Total liabilities reached approximately $7.83 billion, with current liabilities at $6.93 billion and non-current liabilities at $897.76 million[38]. Shareholder Information - The total number of shareholders at the end of the reporting period was 144,917[7]. - The largest shareholder, Meng Qingshan, held 27.48% of the shares, amounting to 854,103,033 shares[7]. - Total equity increased to CNY 6,813,914,442.65 in Q1 2019 from CNY 6,775,722,811.43 in Q1 2018, reflecting a growth of 0.6%[21]. Investment and Development - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[4]. - The company reported non-operating income of CNY 38,241,532.59, primarily from government subsidies and other non-recurring gains[6]. - The company achieved investment income of CNY 41,632,829.52 in Q1 2019, a substantial increase from CNY 7,125,863.85 in Q1 2018[24]. Other Financial Metrics - The weighted average return on equity increased by 0.99 percentage points to 3.68%[4]. - The company's financial assets measured at fair value and recognized in profit or loss decreased by 96.49% to ¥1,204.90 million from ¥3,432.95 million, primarily due to the impact of exchange rate fluctuations on forward foreign exchange hedging[9]. - Research and development expenses for Q1 2019 were CNY 6,097,034.76, slightly down from CNY 6,292,303.51 in Q1 2018[21].
梅花生物(600873) - 2019 Q1 - 季度财报